Cardiovascular Trials and Other Broward General Research Studies

Through the approval of the Broward Health Institutional Review Board, Broward General Medical Center offers pharmaceutical-sponsored FDA-approved cardiovascular clinical trials to the community. These various pharmaceutical sponsored trials involve cutting-edge cardiovascular related areas to study cardiac disease, anticoagulants or antithrombotics, blood pressure control, cholesterol control, atrial fibrillation, interventional and cardiology, and diabetes, as well as cardiac device trials.

Cardiovascular clinical trial research is done to help doctors to find a better way to treat and diagnose patients with cardiac disease. The decision to enroll in a clinical trial is completely voluntary. Each trial offers its own opportunities and risks, but many research volunteers find that clinical trials offer these common benefits:

• opportunity for health care provided by leading physicians in the field of cardiac research
• access to new drugs and interventions before they are widely available
• for you to have a more active role in your own health care
• close monitoring of your health care and any side effects
• you may be the first to benefit, if the approach being studied is found to be helpful to the disease being studied
• an opportunity to make a valuable contribution to cardiac research

Please review the following clinical trials, and if you think that you may qualify and may wish to participate you can call the senior research nurses at the cardiovascular research department. Please call Broward General Medical Center Cardiovascular Research and leave your name and number to 954-468-5237 along with the study name that you think that you may qualify for and a research nurse will contact you.

For further information, please visit: http://www.clinicaltrials.gov/

Clinical Trials List

December 2011 - The following trials are open for enrollment to new patients:

SOLID TIMI-52: SB480848-033 - A clinical outcomes study of Darapladib versus Placebo in subjects following Acute Coronary Syndrome to compare the incidence of Major Adverse Cardiovascular Events (MACE). CLOSED TO ENROLLMENT Sponsor: GlaxoSmithKline Investigator: Dr. Arnoux Blanchard

VISTA-16: AN-CVD2233 - Evaluation of the safety and efficacy of Short-term A-002 Treatment in subjects with Acute Coronary Syndromes. Sponsor: ANTHERA Pharmaceuticals Investigator: Dr. Arnoux Blanchard

ALECARDIO: BC22140A ROW - Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent Acute Coronary Syndrome (ACS) event and Type 2 Diabetes Mellitus (T2D). Sponsor: ROCHE Pharmaceuticals Investigator: Dr. David Perloff

PARADIGM: LCZ696B2314 - A multicenter, randomized, double-blind, parallel group, active-contrilled study to evaluate the efficacy and safety of LCZ696 compared to Enalapril on morbidity and mortality In patients with Chronic Heart Failure and Reduced Ejection Fraction.  Sponsor: NOVARTIS Investigator: Dr. Ricardo Vicuna

BCX1812-303 - A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects with Confirmed or Suspected Influenza Infection Sponsor: Biocryst Investigator: Dr. Gary Richmond - call 954-524-2250

Please call the Principal Investigator or Study coordinator with any questions or potential subjects.